
Opinion|Videos|January 2, 2025
Emerging Data for Odronextamab in DLBCL
Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
RSV Vaccination Effective in Older Adults, but Protection Declines Over Time
3
FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population
4
Older Adults Drive Hospitalizations, Costs in the US 2024-2025 Influenza Season
5













































